C12N 2750/14234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14234 (Use of virus or viral component as vaccine) appears on 6 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 9
- Assignees
- 4
- Inventors
- 12
- Latest grant
- 16 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 2 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 2 | 1 |
By publication year.
Recent patents
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells16 Jul 2024US 12,037,597 B2The Catholic University of America
- Immunogenic combination compositions and uses thereof13 Feb 2024US 11,896,636 B2Glaxosmithkline Biologicals SA
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells26 Oct 2021US 11,155,835 B2The Catholic University of America
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases18 May 2021US 11,008,367 B2University of Louisville Research Foundation, Inc.
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases26 Feb 2019US 10,214,565 B2University of Louisville Research Foundation, Inc.
- Immunogenic combination compositions and uses thereof14 Mar 2024US 2024/0082329 A1Glaxosmithkline Biologicals SA
- Novel erythroparvovirus associated with respiratory distress in equine26 Oct 2023US 2023/0340032 A1Intervet Inc.
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells13 Jan 2022US 2022/0010335 A1The Catholic University of America
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases23 Sep 2021US 2021/0292372 A1University of Louisville Research Foundation, Inc.
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells25 Feb 2021US 2021/0054410 A1The Catholic University of America
Most cited
By later US patents
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells2US 11,155,835 B2The Catholic University of America · 2021
- Compositions and methods for treating, including preventing, parvovirus infections and related diseases1US 10,214,565 B2University of Louisville Research Foundation, Inc. · 2019